Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Clive S. Zent, Charla R. Secreto, Betsy R. LaPlant, Nancy D. Bone, Timothy G. Call, Tait D. Shanafelt, Diane F. Jelinek, Renee C. Tschumper, Neil E. Kay

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) is not well understood. We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity (CDC) although a subpopulation of CLL cells had intrinsic resistance. Rituximab had no direct cytotoxicity and caused minimal CDC in cells from most patients. These data suggest that CDC has a therapeutic role in patients treated with alemtuzumab and that measures to decrease resistance to CDC could increase efficacy.

Original languageEnglish (US)
Pages (from-to)1849-1856
Number of pages8
JournalLeukemia Research
Volume32
Issue number12
DOIs
StatePublished - Dec 2008

Keywords

  • Alemtuzumab
  • Chronic lymphocytic leukemia (CLL)
  • Complement
  • Cytotoxicity
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab'. Together they form a unique fingerprint.

Cite this